Oramed Pharmaceuticals Issues Letter to Shareholders
Key Highlights – expected completion in YR 2025: OraTech Pharmaceuticals Inc. – A new joint venture focused on oral insulin development, with planned U.S. Phase 3 trials. Distribution of majority of Oramed’s holding in OraTech to Oramed shareholders via dividend planned to coincide with OraTech’s
